{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:18:57Z","timestamp":1792441137314,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Hepatocellular carcinoma (HCC) is typically detected only at advanced stages when treatment options are limited. Most of the current HCC risk models focus on patients with viral hepatitis or diagnosed cirrhosis or require variables not routinely available in clinical care.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify modifiable HCC risk factors in the general population and to develop a risk score to inform HCC screening and risk-factor modification interventions for high-risk individuals without viral hepatitis or decompensated cirrhosis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study analyzed demographic, clinical, laboratory, and diagnostic data from the US Department of Veterans Affairs (VA) electronic health records. Data were divided into development and validation samples. Veterans aged 30 to 95 years were included, and those with hepatitis B or C virus infection, hepatic decompensation, or prevalent HCC were excluded. Patients were followed up until the occurrence of HCC diagnosis, death, or December 31, 2021. A Cox proportional hazards regression model for 10-year risk of HCC was developed and used to create an HCC risk score, and performance in development and validation samples and in patient subgroups was evaluated. One outpatient visit date per person at least 18 months after VA entry, between October 1, 2007, and March 31, 2020, was randomly selected and used as the index date for the start of follow-up. Analyses were performed from March 2023 to May 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Age, sex, race and ethnicity, body mass index, liver fibrosis (detected with Fibrosis-4 Index [FIB-4]), diabetes status, smoking status, and alcohol use.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n First HCC diagnosis during follow-up. This information was ascertained from VA national cancer registry topography and histology codes and from\n International Classification of Diseases, Ninth Revision<\/jats:italic>\n and\n International Statistical Classification of Diseases, Tenth Revision, Clinical Modification<\/jats:italic>\n diagnosis codes for the inpatient or outpatient visits.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study of 6\u202f509\u202f288 veterans included 6 048 917 males (92.9%), with a median (IQR) age of 65 (54-74) years, who identified as being of Hispanic (5.3%), non-Hispanic Black (15.0%), non-Hispanic White (68.9%), or other (4.6%) race and ethnicity. Overall, 15\u202f142 patients (0.2%) developed HCC, 69.5% of whom had FIB-4 of 3.25 or lower at baseline. While FIB-4 was the most important variable, age, sex, race and ethnicity, body mass index, diabetes, smoking, and alcohol use were also informative. Discrimination in the development sample was better than FIB-4 alone (C statistic, 0.83 [95% CI, 0.82-0.85] vs 0.79 [95% CI, 0.77-0.80]). The HCC risk score performed consistently well in the validation sample and in all subgroups. A FIB-4 threshold of 3.25 would screen 5.0% of the cohort at a cost of 28 false-positives for every true-positive; a model risk score of 58 would screen 4.7% of the cohort at a cost of 23 false-positives for every true-positive.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this study suggest that a multivariable risk score that uses routinely available clinical data outperforms FIB-4 alone in identifying patients at risk of HCC who do not have viral hepatitis or hepatic decompensation at baseline.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.43608","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T11:00:57Z","timestamp":1730890857000},"page":"e2443608","source":"Crossref","is-referenced-by-count":14,"title":["Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis"],"prefix":"10.1001","volume":"7","author":[{"given":"Ysabel C.","family":"Ilagan-Ying","sequence":"first","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Medicine, Veterans Affairs Connecticut Healthcare, West Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsha S.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Medicine, Veterans Affairs Connecticut Healthcare, West Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet P.","family":"Tate","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Medicine, Veterans Affairs Connecticut Healthcare, West Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Medicine, Veterans Affairs Connecticut Healthcare, West Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Torgersen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Vincent","family":"Lo Re","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Justice","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Medicine, Veterans Affairs Connecticut Healthcare, West Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar H.","family":"Taddei","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Medicine, Veterans Affairs Connecticut Healthcare, West Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"3","key":"zoi241244r1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/hep.32434","article-title":"Risk factors for HCC in contemporary cohorts of patients with cirrhosis.","volume":"77","author":"Kanwal","year":"2023","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"zoi241244r2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma.","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"zoi241244r3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"zoi241244r4","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): update and impact of new nomenclature on the AASLD clinical practice guidance on nonalcoholic fatty liver disease.","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"issue":"6","key":"zoi241244r5","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review.","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"zoi241244r6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"zoi241244r7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/joim.13570","article-title":"Unrecognized liver cirrhosis is common and associated with worse survival in hepatocellular carcinoma: a nationwide cohort study of 3473 patients.","volume":"293","author":"Vaz","year":"2023","journal-title":"J Intern Med"},{"issue":"4","key":"zoi241244r8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi241244r9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10406","key":"zoi241244r10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","article-title":"Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.","volume":"402","author":"Serra-Burriel","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"zoi241244r11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"zoi241244r12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores.","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"zoi241244r13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update.","volume":"75","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu","year":"2021","journal-title":"J Hepatol"},{"issue":"7","key":"zoi241244r14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/jnci\/djz214","article-title":"HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status.","volume":"112","author":"Torgersen","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zoi241244r15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection.","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"zoi241244r16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review.","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"issue":"6","key":"zoi241244r17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.","volume":"160","author":"Lo Re","year":"2014","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi241244r18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/1055-9965.EPI-19-0503","article-title":"Differences in pathology, staging, and treatment between HIV+ and uninfected patients with microscopically confirmed hepatocellular carcinoma.","volume":"29","author":"Torgersen","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"16","key":"zoi241244r19","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test.","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med"},{"issue":"12","key":"zoi241244r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.46604","article-title":"Association between alcohol use disorder and receipt of direct-acting antiviral hepatitis C virus treatment.","volume":"5","author":"Haque","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi241244r21","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/ntr\/ntr206","article-title":"Validating smoking data from the Veteran\u2019s Affairs health factors dataset, an electronic data source.","volume":"13","author":"McGinnis","year":"2011","journal-title":"Nicotine Tob Res"},{"issue":"9","key":"zoi241244r22","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"issue":"10","key":"zoi241244r23","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.14309\/ajg.0000000000000715","article-title":"Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms.","volume":"115","author":"Parikh","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"zoi241244r24","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"zoi241244r25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","article-title":"Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma.","volume":"42","author":"Marrero","year":"2005","journal-title":"J Hepatol"},{"issue":"10","key":"zoi241244r26","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1007\/s11606-021-07197-3","article-title":"Nonalcoholic fatty liver disease underdiagnosis in primary care: what are we missing?","volume":"37","author":"Nielsen","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi241244r27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD).","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"zoi241244r28","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5905357","article-title":"Tobacco smoking and liver cancer risk: potential avenues for carcinogenesis.","volume":"2021","author":"Jain","year":"2021","journal-title":"J Oncol"},{"issue":"7","key":"zoi241244r29","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1007\/s10461-016-1492-9","article-title":"What are the patterns between depression, smoking, unhealthy alcohol use, and other substance use among individuals receiving medical care? A longitudinal study of 5479 participants.","volume":"21","author":"Ruggles","year":"2017","journal-title":"AIDS Behav"},{"issue":"4","key":"zoi241244r30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cgh.2019.08.011","article-title":"Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease.","volume":"18","author":"Grimaudo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"zoi241244r31","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3097","article-title":"Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States.","volume":"35","author":"Aguayo-Mazzucato","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"zoi241244r32","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5323061","article-title":"Speculation of the time-dependent change of FIB4 index in patients with nonalcoholic fatty liver disease: a retrospective study.","volume":"2018","author":"Miyata","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"11","key":"zoi241244r33","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population.","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2825810\/ilaganying_2024_oi_241244_1765815556.19465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:00:38Z","timestamp":1765900838000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2825810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.43608","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}